Reinfection with hepatitis C virus following sustained virological response in injection drug users.
about
KASL clinical practice guidelines: management of hepatitis CInjecting drug use: A vector for the introduction of new hepatitis C virus genotypesPsychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implicationsHepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factorsTreatment of hepatitis C as prevention: a modeling case study in VietnamImpact of Hepatitis C Treatment as Prevention for People Who Inject Drugs is sensitive to contact network structure.Gaining greater insight into HCV emergence in HIV-infected men who have sex with men: the HEPAIG Study.Hepatitis C transmission and treatment in contact networks of people who inject drugs.Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidenceHepatitis C virus reinfection and superinfection among treated and untreated participants with recent infectionHepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.Global control of hepatitis C: where challenge meets opportunityHigh rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study.Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.The effects of needle-sharing and opioid substitution therapy on incidence of hepatitis C virus infection and reinfection in people who inject drugs.Negotiating access to medical treatment and the making of patient citizenship: the case of hepatitis C treatment.Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon-ribavirin-based therapy.HCV reinfection incidence among individuals treated for recent infection.Prisons, prisoners, and hepatitis C.How cost-effective is hepatitis C virus treatment for people who inject drugs?The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine.KASL clinical practice guidelines: management of hepatitis C.A Guide to the Economics of Hepatitis C Virus Cure in 2017
P2860
Q26752471-76D4985E-48CA-4D64-A181-34CEC80A73A9Q26781991-939958DD-08B7-4350-800A-BB809ED8A503Q26798477-321A3027-71AC-4FE0-932F-5D7FA85D0643Q26853671-1D57E143-10F3-4651-8B73-BF03096DCD90Q28482272-868BC0E2-A627-4738-8906-6FE3EA105F90Q33687240-AB52940E-3255-45BB-80AA-BA314614F8F8Q34117484-A96393A9-AD6E-47C1-A2B4-E9A3E8EB3D89Q35040866-4FCE78CD-EFF4-4AC0-A135-140470AC703EQ35540200-CEDE2287-DEDE-4E54-94B1-C1D2B1BC23B9Q35846408-969F298E-F37B-4AF4-AB76-2C04DEA896A1Q36607811-4A5FA23C-2BB3-481F-81B4-3E9D219722ADQ37077112-5039E74A-8D49-460A-9554-B4FDB04ABBFDQ37288631-7EBBA0A0-4584-4DDB-8394-42F235895AF3Q38050834-69533E74-1E55-4CDC-B64F-F7BCED87418AQ38123948-32A3C491-EA03-434E-B712-4438680B7E28Q38381584-C3D2E19D-C6E5-4691-9E75-FEFCADD8F45DQ38407675-3D975638-6162-4F6F-955B-D8E81EF4B59FQ38692113-58F81C1D-4E7A-406A-9806-55AFE94CFA2CQ39123236-9CEA3F33-D799-49D2-9DF5-E8D6713734D4Q39395685-31EE8B05-1F70-4B7A-879C-1BA535B1E177Q40148468-181AAB92-1F7E-47A1-B583-18D685577563Q40393982-64CB882A-C04C-452D-9CB8-2360B16E1674Q42998168-5DB76C84-CB64-4421-A15C-D9A139C694E5Q43688887-34EC9018-B662-4FA0-ACF6-BBBA67AF67C5Q45324462-5F3D8D25-ADC3-4DCC-B550-2824B09FB0A1Q51836024-49C3313F-AC4E-41B6-87CE-D9B8B1EFD50BQ56654943-3FA37658-6515-413F-8815-D3794FAB0F1B
P2860
Reinfection with hepatitis C virus following sustained virological response in injection drug users.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Reinfection with hepatitis C v ...... ponse in injection drug users.
@en
Reinfection with hepatitis C v ...... ponse in injection drug users.
@nl
type
label
Reinfection with hepatitis C v ...... ponse in injection drug users.
@en
Reinfection with hepatitis C v ...... ponse in injection drug users.
@nl
prefLabel
Reinfection with hepatitis C v ...... ponse in injection drug users.
@en
Reinfection with hepatitis C v ...... ponse in injection drug users.
@nl
P2093
P2860
P1476
Reinfection with hepatitis C v ...... ponse in injection drug users.
@en
P2093
Brian Conway
Elizabeth Knight
Fiona Duncan
Gregory J Dore
Jason Grebely
Jesse D Raffa
Krista A Genoway
Lesley Gallagher
Michelle Storms
Tyler Ngai
P2860
P304
P356
10.1111/J.1440-1746.2010.06238.X
P50
P577
2010-07-01T00:00:00Z